{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:33Z","timestamp":1789614153850,"version":"build-2803163510"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104865","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:00:18Z","timestamp":1784044818000},"page":"104865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Latin American consensus on the medical oncologic management of early-stage HR+\/HER2\u2212 breast cancer: Addressing regional disparities in Spanish-speaking countries"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6522-1061","authenticated-orcid":false,"given":"Denis U.","family":"Landaverde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Petracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Grano de Oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0718-9355","authenticated-orcid":false,"given":"Mar\u00eda A.","family":"Bravo Garz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Arce-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Veliz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Amador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0156-5498","authenticated-orcid":false,"given":"Virginia","family":"Enciso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leny","family":"Codas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2475-0570","authenticated-orcid":false,"given":"Fernando","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Valent\u00edn-Bejarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Lemes-Pist\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dami\u00e1n","family":"Hannois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3401-8564","authenticated-orcid":false,"given":"Priyanka","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Guillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"S\u00e1nchez-Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Gavil\u00e1-Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Vidal-Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.canep.2009.10.003","article-title":"Breast cancer as a global health concern","volume":"33","author":"Coughlin","year":"2009","journal-title":"Cancer Epidemiol"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2026.104865_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1075-122X.2006.00199.x","article-title":"Breast cancer in limited-resource countries: an overview of the breast health global initiative 2005 guidelines","volume":"12","author":"Anderson","year":"2006","journal-title":"Breast J"},{"issue":"11","key":"10.1016\/j.breast.2026.104865_bib3","first-page":"913","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Loibl","year":"2023","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.breast.2026.104865_bib4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104865_bib5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104865_bib6","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2022.07.1941","article-title":"ESMO expert consensus statements on cancer survivorship: promoting high-quality survivorship care and research in Europe","volume":"33","author":"Vaz-Luis","year":"2022","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.breast.2026.104865_bib7","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.breast.2026.104865_bib8","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.24.00886","article-title":"Optimal adjuvant chemotherapy and targeted therapy for early breast cancer\u2014Cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update","volume":"42","author":"Freedman","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO\u2013society of surgical oncology guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104865_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.21.02647","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update","volume":"40","author":"Eisen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104865_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1200\/JCO.20.02510","article-title":"Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update","volume":"39","author":"Denduluri","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.21149\/spm.v56i5.7379","article-title":"Breast cancer in Latin America: global burden, patterns, and risk factors","volume":"56","author":"Amadou","year":"2014","journal-title":"Salud Publica Mex"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1590\/S1020-49892002000300007","article-title":"Breast cancer in Latin America and the Caribbean","volume":"11","author":"Robles","year":"2002","journal-title":"Rev Panam Salud P\u00fablic"},{"key":"10.1016\/j.breast.2026.104865_bib14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1200\/EDBK_201315","article-title":"Breast cancer in Latin America: a map of the disease in the region","volume":"38","author":"Cazap","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1634\/theoncologist.2012-0373","article-title":"A review of breast cancer care and outcomes in Latin America","volume":"18","author":"Justo","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104865_bib16","first-page":"223","article-title":"Social inequalities in cancer in Latin America","volume":"9","author":"Murillo","year":"2019","journal-title":"Focus"},{"issue":"8","key":"10.1016\/j.breast.2026.104865_bib17","article-title":"Addressing cancer disparities through community engagement: lessons and best practices","volume":"15","author":"Kale","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.breast.2026.104865_bib18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/cancers16061117","article-title":"Systemic barriers to optimal cancer care in resource-limited countries: jordanian healthcare as an example","volume":"16","author":"Mansour","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004326","article-title":"ACCORD (ACcurate COnsensus reporting document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi","volume":"21","author":"Gattrell","year":"2024","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104865_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.breast.2026.104865_bib21","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104865_bib22","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.breast.2026.104865_bib23","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.breast.2026.104865_bib24","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.breast.2026.104865_bib25","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.breast.2026.104865_bib27","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.breast.2026.104865_bib28","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104865_bib29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"6871","key":"10.1016\/j.breast.2026.104865_bib30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"Van't Veer","year":"2002","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.breast.2026.104865_bib31","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Bernard","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104865_bib32","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2\u2212 breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.breast.2026.104865_bib33","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1200\/JCO.2015.65.2289","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline","volume":"34","author":"Harris","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.breast.2026.104865_bib34","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104865_bib35","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s12094-024-03541-1","article-title":"Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish society of medical oncology and the Spanish society of pathology","volume":"26","author":"Colomer","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.breast.2026.104865_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.10.037","article-title":"Clinical impact of somatic genomic testing on breast cancer care","volume":"37","author":"Khalid","year":"2025","journal-title":"Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/1557988319847856","article-title":"Oncotype DX for comprehensive treatment in male breast cancer: a case report and literature review","volume":"13","author":"Zheng","year":"2019","journal-title":"Am J Mens Health"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000360793","article-title":"The 21-gene recurrence score assay (Oncotype DX\u2122) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort","volume":"87","author":"Grenader","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.breast.2026.104865_bib41","series-title":"Oncotype DX breast recurrence score reveals sex-related differences in mortality prediction in patients with early-stage ER-positive breast cancer","author":"Wang","year":"2019"},{"key":"10.1016\/j.breast.2026.104865_bib42","first-page":"39","article-title":"Evaluation of multiple transcriptomic gene risk signatures in male breast cancer","volume":"7","author":"Peled","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"4_Supplement","key":"10.1016\/j.breast.2026.104865_bib43","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-PS14-11","article-title":"Abstract PS14-11: differential gene expression analysis and clinical utility of MammaPrint and BluePrint in male breast cancer patients","volume":"81","author":"Crozier","year":"2021","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.breast.2026.104865_bib44","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1245\/s10434-020-08473-y","article-title":"Utility of oncotype DX in male breast cancer patients and impact on chemotherapy administration: a comparative study with female patients","volume":"27","author":"Williams","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10549-010-0814-2","article-title":"The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer","volume":"120","author":"Knauer","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 6","key":"10.1016\/j.breast.2026.104865_bib46","first-page":"153","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up \u2013 surgical aspects","volume":"34","author":"Loibl","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104865_bib47","first-page":"877","article-title":"Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study","volume":"26","author":"Lambertini","year":"2025","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104865_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.18486","article-title":"Clinical outcomes for BRCA pathogenic variant carriers with breast cancer undergoing breast conservation","volume":"7","author":"Wanis","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.9840","article-title":"Long-term oncologic outcome of breast-conserving treatment in patients with breast cancer with BRCA variants","volume":"8","author":"Lee","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib50","first-page":"12","article-title":"Long term oncologic outcome of breast conserving treatment in BRCA1\/2 pathogenic variant carriers","volume":"160","author":"Nara","year":"2025","journal-title":"JAMA Surg"},{"issue":"29","key":"10.1016\/j.breast.2026.104865_bib51","first-page":"2915","article-title":"Management of hereditary breast cancer","volume":"38","author":"Kurian","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102974","article-title":"Pan-asian adapted ESMO clinical practice guidelines for early breast cancer: alignment with a meta-analysis comparing BCT versus mastectomy in BRCA-positive women","volume":"9","author":"Park","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib53","first-page":"45","article-title":"Assessment of residual breast volume after skin\/nipple sparing mastectomy","volume":"186","author":"Kwon","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104865_bib54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/abs-24-33","article-title":"Improving value-concordant shared decision making through the use of patient decision aids in breast cancer: a narrative review","volume":"9","author":"Roy","year":"2025","journal-title":"Ann Breast Surg"},{"key":"10.1016\/j.breast.2026.104865_bib55","first-page":"1123","article-title":"Determinants valued by breast cancer patients: a scoping review","volume":"17","author":"P\u00e9rez","year":"2023","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"10.1016\/j.breast.2026.104865_bib56","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00404-018-5035-7","article-title":"Adaptation and qualitative evaluation of encounter decision aids in breast cancer care","volume":"299","author":"Hahlweg","year":"2019","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"10.1016\/j.breast.2026.104865_bib57","first-page":"102","article-title":"Shared decision-making reduces decisional conflict in breast reconstruction: a prospective study","volume":"38","author":"Navarro","year":"2024","journal-title":"Green J Plast Surg"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib58","first-page":"99","article-title":"Oncologist communication training and SDM impact: a randomized trial","volume":"32","author":"Thompson","year":"2024","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.breast.2026.104865_bib59","first-page":"134","article-title":"Sexual function in breast cancer patients: a review of the literature","volume":"49","author":"Lopes","year":"2023","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib60","first-page":"167","article-title":"Prevalence of sexual dysfunction in breast cancer survivors: a population-based cohort study","volume":"15","author":"Basson","year":"2024","journal-title":"J Midlife Health"},{"issue":"4","key":"10.1016\/j.breast.2026.104865_bib61","first-page":"193","article-title":"Disfunci\u00f3n sexual en mujeres diagnosticadas y tratadas de c\u00e1ncer de mama","volume":"34","author":"C\u00f3rdoba","year":"2020","journal-title":"Revisiones C\u00e1ncer"},{"key":"10.1016\/j.breast.2026.104865_bib62","first-page":"176","article-title":"Sexual dysfunction in women with breast cancer of northeast Brazil","volume":"13","author":"Silva","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib63","first-page":"21","article-title":"La importancia de recuperar la vida sexual tras el c\u00e1ncer de mama","volume":"13","author":"Castelo-Branco","year":"2022","journal-title":"Raed Acad Med"},{"key":"10.1016\/j.breast.2026.104865_bib64","first-page":"5863","article-title":"Breast cancer and sexual function","volume":"10","author":"Boswell","year":"2023","journal-title":"Tau AME"},{"issue":"2","key":"10.1016\/j.breast.2026.104865_bib65","first-page":"139","article-title":"Managing sexual health challenges in breast cancer survivors","volume":"18","author":"Olsson","year":"2024","journal-title":"Curr Opin Support Palliat Care"},{"issue":"2","key":"10.1016\/j.breast.2026.104865_bib66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/009262300278597","article-title":"The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function","volume":"26","author":"Rosen","year":"2000","journal-title":"J Sex Marital Ther"},{"issue":"7","key":"10.1016\/j.breast.2026.104865_bib67","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","article-title":"Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer","volume":"22","author":"Franzoi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.breast.2026.104865_bib68","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2013.49.2678","article-title":"Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update","volume":"31","author":"Loren","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib69","first-page":"10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2002-23520","article-title":"Preliminary experience with orthotopic and heterotopic transplantation of ovarian cortical strips","volume":"20","author":"Oktay","year":"2002","journal-title":"Semin Reprod Med"},{"issue":"35","key":"10.1016\/j.breast.2026.104865_bib71","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1200\/JCO.2009.23.0250","article-title":"Physician referral for fertility preservation in oncology patients: a national study of practice behaviors","volume":"27","author":"Quinn","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib72","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.fertnstert.2017.05.024","article-title":"Update on fertility preservation from the Barcelona international society for fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives","volume":"108","author":"Martinez","year":"2017","journal-title":"Fertil Steril"},{"issue":"18","key":"10.1016\/j.breast.2026.104865_bib73","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1002\/cncr.26649","article-title":"Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer","volume":"118","author":"Letourneau","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2026.104865_bib74","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2212856","article-title":"Temporary interruption of endocrine therapy to attempt pregnancy in young women with hormone receptor-positive early breast cancer","volume":"388","author":"Partridge","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104865_bib75","series-title":"ESMO congress","article-title":"5-year follow-up results from the POSITIVE (pregnancy outcome and safety of interrupting therapy for women with endocrine responsive breast cancer) trial","author":"Pagani","year":"2025"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12609-025-00571-8","article-title":"Impact of breast cancer systemic therapies on fertility","volume":"17","author":"Hundal","year":"2025","journal-title":"Curr Breast Cancer Rep"},{"issue":"12","key":"10.1016\/j.breast.2026.104865_bib77","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility preservation in people with cancer: ASCO guideline update","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104865_bib78","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1038\/s41598-025-91197-4","article-title":"Prevalence and impact of fertility preservation among young women with breast cancer","volume":"15","author":"Chen","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104865_bib79","first-page":"7549","article-title":"Fertility counseling and preservation in young breast cancer patients","volume":"14","author":"Nakayama","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.breast.2026.104865_bib80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminoncol.2020.05.010","article-title":"Management of hormone receptor-positive, HER2-negative early breast cancer","volume":"47","author":"Walsh","year":"2020","journal-title":"Semin Oncol"},{"issue":"26","key":"10.1016\/j.breast.2026.104865_bib81","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer","volume":"383","author":"Burstein","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.breast.2026.104865_bib82","first-page":"1457","article-title":"Long-term effect of adjuvant tamoxifen by molecular subtype","volume":"5","author":"Lindstr\u00f6m","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104865_bib83","first-page":"1","article-title":"Personalizing adjuvant endocrine therapy for early-stage hormone receptor-positive breast cancer","volume":"42","author":"Burstein","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"28","key":"10.1016\/j.breast.2026.104865_bib84","first-page":"4639","article-title":"Outcome prediction for estrogen receptor-positive breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104865_bib85","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.2016.71.5292","article-title":"Neoadjuvant endocrine therapy for hormone receptor-positive breast cancer: ASCO guideline","volume":"41","author":"Burstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9793","key":"10.1016\/j.breast.2026.104865_bib86","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104865_bib87","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7150\/jca.7668","article-title":"The prognostic and predictive impact of low estrogen receptor: a majority of low (1\u201310%) ER positive breast cancers behave like hormone receptor negative tumors","volume":"5","author":"Elston","year":"2014","journal-title":"J Cancer"},{"issue":"16","key":"10.1016\/j.breast.2026.104865_bib88","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO-24-02263","article-title":"Endocrine therapy omission in estrogen receptor-low (1%-10%) early-stage breast cancer","volume":"43","author":"Choong","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104865_bib89","first-page":"1","article-title":"Estrogen receptor-low positive breast cancer: historical perspective and recent advancements","volume":"147","author":"Zhang","year":"2025","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105057","article-title":"Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance","volume":"10","author":"Lobo-Martins","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.breast.2026.104865_bib91","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104865_bib92","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.breast.2026.104865_bib93","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"issue":"9993","key":"10.1016\/j.breast.2026.104865_bib94","first-page":"446","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer: meta-analysis of individual patient-level data from randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib95","article-title":"Efficacy and safety of ovarian suppression in combination with endocrine therapy in premenopausal women with hormone receptor-positive breast cancer: a meta-analysis","volume":"6","author":"Sun","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104865_bib96","first-page":"515","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: ASCO guideline update","volume":"42","author":"Rugo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib98","first-page":"523","article-title":"Gonadotropin-releasing hormone analogs during chemotherapy for the prevention of chemotherapy-induced ovarian failure in breast cancer patients: a meta-analysis of randomized trials","volume":"32","author":"Del Mastro","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib99","first-page":"683","article-title":"Incomplete ovarian suppression in premenopausal breast cancer patients receiving luteinizing hormone-releasing hormone agonists and aromatase inhibitors","volume":"184","author":"Paik","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.breast.2026.104865_bib100","first-page":"567","article-title":"De-escalating and escalating treatments for early-stage breast cancer: st. Gallen international expert consensus conference on the primary therapy of early breast cancer 2023","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"},{"issue":"9869","key":"10.1016\/j.breast.2026.104865_bib101","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"18_suppl","key":"10.1016\/j.breast.2026.104865_bib102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.breast.2026.104865_bib103","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib104","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/jnci\/djx134","article-title":"Optimal duration of extended adjuvant endocrine therapy for early breast cancer: results of the IDEAL trial (BOOG 2006-05)","volume":"110","author":"Blok","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.breast.2026.104865_bib105","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2026.104865_bib106","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","article-title":"Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 trial","volume":"26","author":"Mamounas","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib107","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib108","first-page":"918","article-title":"Abemaciclib combined with endocrine therapy for adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer: monarche","volume":"41","author":"Johnston","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"10.1016\/j.breast.2026.104865_bib109","doi-asserted-by":"crossref","first-page":"LBA500","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500","article-title":"NATALEE trial: adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in HR+\/HER2\u2212 early breast cancer. ASCO annual meeting 2023","volume":"41","author":"Slamon","year":"2023","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.breast.2026.104865_bib110","first-page":"1675","article-title":"NATALEE trial: ribociclib + endocrine therapy in stage II and III HR+\/HER2\u2212 early breast cancer","volume":"389","author":"Slamon","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.breast.2026.104865_bib111","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"astogi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104865_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105858","article-title":"Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival","volume":"10","author":"Crown","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.breast.2026.104865_bib113","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.breast.2026.104865_bib114","article-title":"Subgroup analyses of NATALEE trial: ribociclib efficacy across nodal status and menopausal groups. ESMO breast cancer congress 2024, abstract 1130","volume":"9","author":"Fasching","year":"2024","journal-title":"ESMO Open"},{"issue":"25","key":"10.1016\/j.breast.2026.104865_bib115","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib116","first-page":"299","article-title":"Olaparib for high-risk early breast cancer and germline BRCA mutation: overall survival results from the OlympiA trial","volume":"41","author":"Tolaney","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib118","first-page":"41","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2023","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib119","first-page":"414","article-title":"Breast cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib120","first-page":"484","article-title":"NCCN clinical practice guidelines in oncology: Breast cancer. Version 6.2024","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib121","first-page":"12","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"34","author":"Cardoso","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104865_bib122","first-page":"345","article-title":"Meta-analysis of dose-dense chemotherapy","volume":"170","author":"Goldvaser","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"9472","key":"10.1016\/j.breast.2026.104865_bib123","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"issue":"38","key":"10.1016\/j.breast.2026.104865_bib124","article-title":"Meta-analysis of neoadjuvant versus adjuvant chemotherapy in operable breast cancer","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.breast.2026.104865_bib125","first-page":"1234","article-title":"Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage HR+\/HER2\u2212 breast cancer: a retrospective SEER cohort","volume":"14","author":"Shang","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.breast.2026.104865_bib126","first-page":"29","article-title":"Prediction of CT benefit by MammaPrint in HR+\/HER2\u2212 early breast cancer (real-world)","volume":"38","author":"Audeh","year":"2024","journal-title":"Miami Breast Cancer Conf"},{"issue":"2","key":"10.1016\/j.breast.2026.104865_bib127","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib128","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104865_bib129","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104865_bib130","first-page":"130","article-title":"The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.breast.2026.104865_bib131","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1056\/NEJMra1707939","article-title":"Breast cancer in men","volume":"378","author":"Giordano","year":"2018","journal-title":"N Engl J Med"},{"issue":"9510","key":"10.1016\/j.breast.2026.104865_bib132","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(06)68226-3","article-title":"Male breast cancer","volume":"367","author":"Fentiman","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib133","first-page":"215","article-title":"Adjuvant ribociclib + endocrine therapy in early breast cancer: NATALEE trial","volume":"389","author":"Harbeck","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.breast.2026.104865_bib134","first-page":"1475","article-title":"Adjuvant therapy with tamoxifen or aromatase inhibitors in male breast cancer","volume":"108","author":"Eggemann","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib135","first-page":"555","article-title":"Endocrine therapy in men with breast cancer: a systematic review","volume":"145","author":"Zagouri","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2026.104865_bib136","first-page":"e497","article-title":"Adjuvant hormonal therapy in male breast cancer: real-world data and systematic review","volume":"20","author":"Leone","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"10.1016\/j.breast.2026.104865_bib137","first-page":"1916","article-title":"Physical activity and risk of breast cancer recurrence and mortality: a systematic review and meta-analysis","volume":"29","author":"Friedenreich","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"30","key":"10.1016\/j.breast.2026.104865_bib138","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2012.42.0638","article-title":"Lifestyle interventions in breast cancer survivors: the potential impact of physical activity and diet","volume":"30","author":"Ligibel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib139","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.298.3.289","article-title":"Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's healthy eating and living (WHEL) randomized trial","volume":"298","author":"Pierce","year":"2007","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.breast.2026.104865_bib140","first-page":"2820","article-title":"Adherence to mediterranean diet and risk of cancer: an updated systematic review and meta-analysis","volume":"7","author":"Schwingshackl","year":"2015","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.breast.2026.104865_bib141","article-title":"Exercise interventions on health-related quality of life for cancer survivors","author":"Mishra","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"28","key":"10.1016\/j.breast.2026.104865_bib142","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1200\/JCO.2006.08.2024","article-title":"Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial","volume":"25","author":"Courneya","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib143","first-page":"pkz080","article-title":"Physical activity and mortality in cancer survivors: systematic review","volume":"4","author":"Patel","year":"2023","journal-title":"JNCI Cancer Spectr"},{"issue":"20","key":"10.1016\/j.breast.2026.104865_bib144","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1001\/jama.293.20.2479","article-title":"Physical activity and survival after breast cancer diagnosis","volume":"293","author":"Holmes","year":"2005","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.breast.2026.104865_bib145","first-page":"1578","article-title":"Scoping review: post-diagnosis alcohol consumption and breast cancer outcomes","volume":"47","author":"Nomura","year":"2023","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib146","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/alcalc\/agaa012","article-title":"Alcohol consumption by beverage type and risk of breast cancer: a dose-response meta-analysis of prospective cohort studies","volume":"55","author":"Sun","year":"2020","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib147","first-page":"117","article-title":"Smoking and alcohol consumption in breast cancer survivors","volume":"34","author":"Brooks","year":"2025","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib148","first-page":"e23","article-title":"Smoking post-diagnosis associated with increased breast cancer recurrence: systematic review","volume":"25","author":"Kim","year":"2022","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.breast.2026.104865_bib149","first-page":"401","article-title":"Psycho-social experiences of breast cancer survivors: meta-review of qualitative studies","volume":"31","author":"Mitchell","year":"2023","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib150","first-page":"djt316","article-title":"Psychosocial\/supportive care needs of survivors with family and work roles","volume":"106","author":"Hill","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104865_bib151","first-page":"123","article-title":"Systematic review of clinical practice guidelines for long-term breast cancer survivors: care gaps","volume":"132","author":"Puig","year":"2025","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2026.104865_bib152","first-page":"523","article-title":"Psychological and sexual disorders in breast cancer survivors: prevalence and impact","volume":"21","author":"Thapa","year":"2012","journal-title":"Psychooncology"},{"issue":"6","key":"10.1016\/j.breast.2026.104865_bib153","first-page":"1661","article-title":"Quality of life after breast cancer: survivorship and sexuality","volume":"6","author":"Basson","year":"2009","journal-title":"J Sex Med"},{"issue":"17","key":"10.1016\/j.breast.2026.104865_bib154","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.ejca.2005.05.017","article-title":"Quality of life among long-term breast cancer survivors: a systematic review","volume":"41","author":"Mols","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104865_bib155","article-title":"Challenges in youth breast cancer survivors: sexual QoL, work and family","volume":"9","author":"Oberguggenberger","year":"2024","journal-title":"ESMO Open"},{"issue":"51","key":"10.1016\/j.breast.2026.104865_bib156","first-page":"46","article-title":"Psychological responses in breast cancer survivors: ongoing unmet needs","volume":"2015","author":"Ferrell","year":"2015","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"4","key":"10.1016\/j.breast.2026.104865_bib157","first-page":"e121","article-title":"Quality of life and mental health among breast cancer survivors: a UK registry-based study","volume":"14","author":"Halpern","year":"2020","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.breast.2026.104865_bib158","first-page":"432","article-title":"Enhancing early-stage breast cancer survivorship: multidisciplinary approaches","volume":"43","author":"Bliss","year":"2023","journal-title":"ASCO Educ Book"},{"key":"10.1016\/j.breast.2026.104865_bib159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2017.01.002","article-title":"Adolopment\u2014A new term added to the clinical epidemiology lexicon","volume":"81","author":"Tugwell","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.breast.2026.104865_bib160","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2020.0229","article-title":"Prevalence of pathogenic variants in cancer susceptibility genes among women with postmenopausal breast cancer","volume":"323","author":"Kurian","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.breast.2026.104865_bib161","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10549-021-06201-y","article-title":"Multigene assessment of genetic risk for women for two or more breast cancers","volume":"188","author":"Weitzel","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2026.104865_bib162","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000528972","article-title":"Prevalence of pathogenic germline variants in women with non-familial unilateral triple-negative breast cancer","volume":"18","author":"Rhiem","year":"2023","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2026.104865_bib163","article-title":"Barriers and facilitators to provide multidisciplinary care for breast cancer patients in five Latin American countries: a descriptive-interpretative qualitative study","volume":"11","author":"Barrios","year":"2022","journal-title":"Lancet Reg Health, Am"},{"issue":"30","key":"10.1016\/j.breast.2026.104865_bib164","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1200\/JCO.2005.01.6089","article-title":"Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer","volume":"24","author":"Lohrisch","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104865_bib165","first-page":"12","article-title":"Impacto del intervalo de tiempo entre neoadyuvancia y cirug\u00eda en las pacientes con c\u00e1ncer de mama","volume":"7","author":"Rebaza","year":"2017","journal-title":"Carcinos"},{"key":"10.1016\/j.breast.2026.104865_bib166","first-page":"897","article-title":"Barriers in Latin America for the management of locally advanced breast cancer","volume":"13","author":"Pinto","year":"2019","journal-title":"ecancermedicalscience"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:29:08Z","timestamp":1789612148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762600175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":162,"alternative-id":["S096097762600175X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104865","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latin American consensus on the medical oncologic management of early-stage HR+\/HER2\u2212 breast cancer: Addressing regional disparities in Spanish-speaking countries","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104865"}}